Swiss drugmaker Roche will combine two production operations in Basel in a move that will cut up to 190 jobs over this year and next, it said on Thursday.
Merging the active substance and small molecule drug production lines reflects the company’s changing portfolio, focusing more on specialised drugs in smaller volumes, it said in a statement.
Small molecule substances are used in the large majority of most traditional drugs.
The company said lower overall capacity will be required as its older drugs, which require significantly higher production volumes, lose patent protection.
Roche employs about 15,000 staff in Switzerland.
By Paul Arnold
Source: Reuters
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
